PE20231680A1 - Anticuerpos anti-cd30l y usos de estos - Google Patents
Anticuerpos anti-cd30l y usos de estosInfo
- Publication number
- PE20231680A1 PE20231680A1 PE2023002377A PE2023002377A PE20231680A1 PE 20231680 A1 PE20231680 A1 PE 20231680A1 PE 2023002377 A PE2023002377 A PE 2023002377A PE 2023002377 A PE2023002377 A PE 2023002377A PE 20231680 A1 PE20231680 A1 PE 20231680A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- nos
- cd30l
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150373P | 2021-02-17 | 2021-02-17 | |
| PCT/US2022/016565 WO2022177963A1 (en) | 2021-02-17 | 2022-02-16 | Anti-cd30l antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231680A1 true PE20231680A1 (es) | 2023-10-19 |
Family
ID=82931610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002377A PE20231680A1 (es) | 2021-02-17 | 2022-02-16 | Anticuerpos anti-cd30l y usos de estos |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20240254246A1 (enExample) |
| EP (1) | EP4294840A4 (enExample) |
| JP (2) | JP7559257B2 (enExample) |
| KR (1) | KR20230157356A (enExample) |
| CN (2) | CN117255802A (enExample) |
| AR (1) | AR124895A1 (enExample) |
| AU (1) | AU2022224561A1 (enExample) |
| BR (1) | BR112023016445A2 (enExample) |
| CA (1) | CA3208060A1 (enExample) |
| CL (2) | CL2023002393A1 (enExample) |
| CO (1) | CO2023011962A2 (enExample) |
| CR (1) | CR20230445A (enExample) |
| EC (1) | ECSP23070234A (enExample) |
| GE (4) | GEAP202616911A (enExample) |
| IL (1) | IL305146A (enExample) |
| JO (1) | JOP20230186A1 (enExample) |
| MX (1) | MX2023009621A (enExample) |
| PE (1) | PE20231680A1 (enExample) |
| TW (1) | TW202302637A (enExample) |
| WO (1) | WO2022177963A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4081241A4 (en) | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| PE20231680A1 (es) * | 2021-02-17 | 2023-10-19 | Dr Falk Pharma Gmbh | Anticuerpos anti-cd30l y usos de estos |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| AU2023315888A1 (en) * | 2022-07-25 | 2025-02-06 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies, formulations therefor, and uses thereof |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
| KR20260074680A (ko) * | 2023-09-12 | 2026-05-26 | 암젠 인크 | 항-cd30l 항체 및 이의 용도 |
| CN122055382A (zh) * | 2023-10-03 | 2026-05-15 | 国立大学法人京都大学 | 靶向人cd153的抗体和嵌合抗原受体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ATE311895T1 (de) * | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1667730T3 (da) | 2003-08-20 | 2013-09-23 | Univ Miami | Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom |
| WO2013059732A1 (en) * | 2011-10-21 | 2013-04-25 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
| CN104507968B (zh) * | 2012-04-27 | 2019-02-05 | 诺和诺德股份有限公司 | 人cd30配体抗原结合蛋白 |
| EP2945865B1 (en) | 2013-01-18 | 2019-01-09 | LORD Corporation | Active vibration control devices, systems, and methods |
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| WO2017127537A1 (en) | 2016-01-19 | 2017-07-27 | Thomas Blumenthal | Down syndrome biomarkers and uses thereof |
| PT3774897T (pt) * | 2018-04-30 | 2023-11-10 | Cedars Sinai Medical Center | Métodos e sistemas para seleção e tratamento de pacientes com doenças inflamatórias |
| WO2020096046A1 (ja) | 2018-11-09 | 2020-05-14 | 国立大学法人大阪大学 | 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン |
| PE20231680A1 (es) * | 2021-02-17 | 2023-10-19 | Dr Falk Pharma Gmbh | Anticuerpos anti-cd30l y usos de estos |
-
2022
- 2022-02-16 PE PE2023002377A patent/PE20231680A1/es unknown
- 2022-02-16 CN CN202280028982.8A patent/CN117255802A/zh active Pending
- 2022-02-16 CN CN202410189800.6A patent/CN118047872A/zh active Pending
- 2022-02-16 WO PCT/US2022/016565 patent/WO2022177963A1/en not_active Ceased
- 2022-02-16 IL IL305146A patent/IL305146A/en unknown
- 2022-02-16 EP EP22756817.7A patent/EP4294840A4/en active Pending
- 2022-02-16 AR ARP220100318A patent/AR124895A1/es unknown
- 2022-02-16 CR CR20230445A patent/CR20230445A/es unknown
- 2022-02-16 KR KR1020237031681A patent/KR20230157356A/ko active Pending
- 2022-02-16 GE GEAP202616911A patent/GEAP202616911A/en unknown
- 2022-02-16 BR BR112023016445A patent/BR112023016445A2/pt unknown
- 2022-02-16 AU AU2022224561A patent/AU2022224561A1/en active Pending
- 2022-02-16 TW TW111105667A patent/TW202302637A/zh unknown
- 2022-02-16 GE GEAP202216351A patent/GEP20257791B/en unknown
- 2022-02-16 GE GEAP202416351A patent/GEAP202416351A/en unknown
- 2022-02-16 CA CA3208060A patent/CA3208060A1/en active Pending
- 2022-02-16 US US18/546,955 patent/US20240254246A1/en active Pending
- 2022-02-16 JP JP2023549602A patent/JP7559257B2/ja active Active
- 2022-02-16 MX MX2023009621A patent/MX2023009621A/es unknown
- 2022-02-16 GE GEAP202516710A patent/GEAP202516710A/en unknown
- 2022-08-26 US US17/822,598 patent/US11866505B2/en active Active
-
2023
- 2023-08-09 JO JOJO/P/2023/0186A patent/JOP20230186A1/ar unknown
- 2023-08-14 CL CL2023002393A patent/CL2023002393A1/es unknown
- 2023-09-08 CO CONC2023/0011962A patent/CO2023011962A2/es unknown
- 2023-09-14 EC ECSENADI202370234A patent/ECSP23070234A/es unknown
- 2023-11-15 US US18/510,511 patent/US12516126B2/en active Active
-
2024
- 2024-09-17 JP JP2024160401A patent/JP2025004013A/ja active Pending
-
2025
- 2025-11-25 US US19/400,372 patent/US20260209372A1/en active Pending
-
2026
- 2026-03-25 CL CL2026000881A patent/CL2026000881A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| PE20211709A1 (es) | Anticuerpos que reconocen tau | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| PE20251278A1 (es) | Anticuerpos anti-tl1a y metodos de uso de los mismos | |
| JP2020037555A5 (enExample) | ||
| JP2021514973A5 (enExample) | ||
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2018510636A5 (enExample) | ||
| JP2017113028A5 (enExample) | ||
| MX2013012862A (es) | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. | |
| PE20190212A1 (es) | Anticuerpos anti_ige | |
| AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| RU2022108410A (ru) | Терапевтические антитела против лиганда cd40 | |
| AR124895A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| PE20250390A1 (es) | Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares |